BR112023024595A2 - Receptores de células t direcionando mutações ras e usos dos mesmos - Google Patents

Receptores de células t direcionando mutações ras e usos dos mesmos

Info

Publication number
BR112023024595A2
BR112023024595A2 BR112023024595A BR112023024595A BR112023024595A2 BR 112023024595 A2 BR112023024595 A2 BR 112023024595A2 BR 112023024595 A BR112023024595 A BR 112023024595A BR 112023024595 A BR112023024595 A BR 112023024595A BR 112023024595 A2 BR112023024595 A2 BR 112023024595A2
Authority
BR
Brazil
Prior art keywords
cell receptors
ras mutations
receptors targeting
targeting ras
ras
Prior art date
Application number
BR112023024595A
Other languages
English (en)
Portuguese (pt)
Inventor
A Klebanoff Christopher
S Chandran Smita
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of BR112023024595A2 publication Critical patent/BR112023024595A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
BR112023024595A 2021-05-25 2022-05-25 Receptores de células t direcionando mutações ras e usos dos mesmos BR112023024595A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163192783P 2021-05-25 2021-05-25
PCT/US2022/030814 WO2022251283A1 (en) 2021-05-25 2022-05-25 T cell receptors targeting ras mutations and uses thereof

Publications (1)

Publication Number Publication Date
BR112023024595A2 true BR112023024595A2 (pt) 2024-02-15

Family

ID=84230235

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023024595A BR112023024595A2 (pt) 2021-05-25 2022-05-25 Receptores de células t direcionando mutações ras e usos dos mesmos

Country Status (11)

Country Link
US (1) US20240091361A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347639A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024520427A (cg-RX-API-DMAC7.html)
KR (1) KR20240013750A (cg-RX-API-DMAC7.html)
CN (1) CN117545766A (cg-RX-API-DMAC7.html)
AU (1) AU2022283277A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024595A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219923A1 (cg-RX-API-DMAC7.html)
IL (1) IL308755A (cg-RX-API-DMAC7.html)
MX (1) MX2023014073A (cg-RX-API-DMAC7.html)
WO (1) WO2022251283A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4573114A4 (en) * 2022-08-19 2026-07-29 Memorial Sloan Kettering Cancer Center T-LYMPHOCYTE RECEPTORS TARGETTING RAS MUTATIONS AND ASSOCIATED USES
US20260232734A1 (en) * 2023-02-27 2026-08-13 Adaptive Biotechnologies Corporation Therapeutic T-Cell Receptors Targeting KRAS G12D
CN118812698A (zh) * 2023-04-19 2024-10-22 香雪生命科学技术(广东)有限公司 一种识别kras突变的高亲和力t细胞受体及其应用
KR20260024373A (ko) * 2023-05-05 2026-02-20 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 다중-수용체 자연 살해 세포
WO2025054164A1 (en) * 2023-09-05 2025-03-13 Bluesphere Bio, Inc. T cell receptors targeting an npm1 neoantigen
AU2024408100A1 (en) * 2023-12-22 2026-08-06 Abata Therapeutics, Inc. Cell therapies for type 1 diabetes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
MX2020001879A (es) * 2017-08-18 2020-07-29 Gritstone Oncology Inc Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
MX2020005765A (es) * 2017-12-04 2020-09-25 Us Health Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
US20200129555A1 (en) * 2018-10-24 2020-04-30 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla-a3-restricted t cell receptors against mutated ras
CA3127673A1 (en) * 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
GB2613715B (en) * 2019-02-20 2023-12-06 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof

Also Published As

Publication number Publication date
EP4347639A1 (en) 2024-04-10
US20240091361A1 (en) 2024-03-21
KR20240013750A (ko) 2024-01-30
WO2022251283A1 (en) 2022-12-01
AU2022283277A9 (en) 2024-01-04
CA3219923A1 (en) 2022-12-01
CN117545766A (zh) 2024-02-09
JP2024520427A (ja) 2024-05-24
AU2022283277A1 (en) 2023-12-14
EP4347639A4 (en) 2025-08-06
IL308755A (en) 2024-01-01
MX2023014073A (es) 2024-02-21

Similar Documents

Publication Publication Date Title
MX2023014073A (es) Receptores de linfocitos t que se dirigen a mutaciones de ras y usos de los mismos.
BR112023022297A2 (pt) Receptores quiméricos que alvejam adgre2 e/ou clec12a e usos dos mesmos
ECSP22051701A (es) Anticuerpos anti-cd73 y usos de estos
Voss et al. Fatty acid synthase contributes to restimulation-induced cell death of human CD4 T cells
Rao et al. AMPK-dependent and independent effects of AICAR and compound C on T-cell responses
Haskó et al. Adenosine: a potential mediator of immunosuppression in multiple organ failure
MX2021001009A (es) Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión específicas de la diana.
BR112019007100A2 (pt) composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
BR112023002150A2 (pt) Anticorpos direcionando egfr e uso dos mesmos
BR112022003826A2 (pt) Métodos para gerar e isolar neurônios de dopamina do mesencéfalo, população celular, composição e kit
Zhdanov et al. Inhibition of telomerase activity and induction of apoptosis by Rhodospirillum rubrum l‐asparaginase in cancer Jurkat cell line and normal human CD4+ T lymphocytes
Kaufmann The human intra-S checkpoint response to UVC-induced DNA damage
MX2023013001A (es) Compuestos para inhibir o degradar itk, composiciones que comprenden los mismos, metodos para su elaboracion y metodos para su uso.
MX2023013723A (es) Polipeptidos de il-21 y construcciones dirigidas.
CL2025001720A1 (es) Productos terapéuticos dirigidos al receptor de somatostatina subtipo 2 (sst2r) y usos de la misma
Lee et al. Marine-derived secondary metabolite, Griseusrazin A, suppresses inflammation through heme oxygenase-1 induction in activated RAW264. 7 macrophages
WO2022010914A3 (en) Brk peptides and methods of use
Adams et al. Proteomic responses of sea urchin embryos to stressful ultraviolet radiation
Seo et al. Rosa gallica and its active compound, cyanidin‐3, 5‐O‐diglucoside, improve skin hydration via the GLK signaling pathway
Kavitha et al. Differential regulation of MRN (Mre11–Rad50–Nbs1) complex subunits and telomerase activity in cancer cells
Saitoh et al. Antitumor activity of Hypsizigus marmoreus. II. Preventive effect against lung metastasis of Lewis lung carcinoma
Figueroa-Hernández et al. Plant products with anti-cancer properties employed in the treatment of bowel cancer: literature review 1985 and 2004.
BR112022024071A2 (pt) Compostos moduladores de tlr2, composições farmacêuticas e usos dos mesmos
Meng et al. Relationship between micronucleus formation and oxidative stress in human vascular endothelial cells under low dose rate irradiation
EA202190370A1 (ru) Инъекционные системы, инъекционные инструменты и связанные с ними способы

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]